Fox Run Management, L.L.C. Macrogenics Inc Transaction History

Fox Run Management, L.L.C.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$4.62 - $7.54 $46,865 - $76,485	-10,144 Reduced 36.64%	17,542 $93,000
Q1 2023 May 12, 2023	SELL	$4.82 - $7.24 $40,666 - $61,083	-8,437 Reduced 23.36%	27,686 $198,000
Q4 2022 Feb 07, 2023	BUY	$3.34 - $6.98 $120,650 - $252,138	36,123 New	36,123 $242,000
Q1 2022 May 10, 2022	SELL	$8.12 - $16.9 $95,742 - $199,267	-11,791 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$15.91 - $21.88 $187,594 - $257,987	11,791 New	11,791 $189,000
Q3 2020 Oct 29, 2020	SELL	$24.69 - $31.6 $230,481 - $294,986	-9,335 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$5.2 - $29.12 $48,542 - $271,835	9,335 New	9,335 $261,000
Q3 2018 Oct 05, 2018	SELL	$19.26 - $23.46 $294,735 - $359,008	-15,303 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$19.78 - $24.67 $302,693 - $377,525	15,303 New	15,303 $316,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.